A Novel Butyrate Generator Helps Modulate the Gut-Brain Axis: A Randomized Double-Blind Placebo-Controlled Clinical Study

Purpose: ButyraGen ® (Registered Trademark of NutriScience Innovations, LLC), generates butyrate, a short-chain fatty acid, in the small intestine without the drawbacks of conventional formulations. Butyrate has roles in metabolism, immunity, and inflammation, and has emerging relevance in gut-brain axis signaling and psychological health. This randomized, double-blind, placebo-controlled trial evaluated ButyraGen’s effects on mood and well-being. Patients and Methods: A starting cohort of 596 adults were randomized and double-blinded to receive 200 mg/day of ButyraGen or placebo for six weeks in a fully virtual study. Validated questionnaires were administered to assess changes in anxiety, depression, and functional outcomes. Analyses followed an Intent-to-Treat protocol, with Minimal Clinically Important Difference (MCID) used to identify meaningful improvements through post-hoc analyses. Results: ButyraGen significantly reduced self-reported anxiety in men, who were over twice as likely to achieve clinically meaningful improvement versus placebo. Across all participants, improvements in feelings of fear and unease were observed. No overall benefit for self-reported depression was seen, but participants without gastrointestinal disease had a twofold greater likelihood of improvement compared to placebo. Further analysis showed improvements in hopelessness and helplessness among younger adults and men. Functional improvements were also seen for reduced distraction and improved social engagement. Conclusion: These results suggest that ButyraGen may supports both psychological and physiological well-being, particularly in men, younger individuals, and those without gastrointestinal disease. Benefits began to appear within weeks two and three and were sustained through six weeks, highlighting its potential as a fast-acting intervention for both gut and brain health, indicative of the gut-brain axis connection. Keywords: ButyraGen, cognitive, digestion, butyrate, mood, psychological well-being

Authors

Institutions

Publication Details

Journal
Nutrition and Dietary Supplements
Published
2025-12-01
DOI
https://doi.org/10.2147/nds.s565532
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Novel Butyrate Generator Helps Modulate the Gut-Brain Axis: A Randomized Double-Blind Placebo-Controlled Clinical Study

Michael D. Lelah, Edward Dosz, Devin Conley
Nutrition and Dietary Supplements
Gut microbiota and health
article

A Novel Butyrate Generator Helps Modulate the Gut-Brain Axis: A Randomized Double-Blind Placebo-Controlled Clinical Study

Michael D. Lelah, Edward Dosz, Devin Conley
article en

Abstract

Purpose: ButyraGen ® (Registered Trademark of NutriScience Innovations, LLC), generates butyrate, a short-chain fatty acid, in the small intestine without the drawbacks of conventional formulations. Butyrate has roles in metabolism, immunity, and inflammation, and has emerging relevance in gut-brain axis signaling and psychological health. This randomized, double-blind, placebo-controlled trial evaluated ButyraGen’s effects on mood and well-being. Patients and Methods: A starting cohort of 596 adults were randomized and double-blinded to receive 200 mg/day of ButyraGen or placebo for six weeks in a fully virtual study. Validated questionnaires were administered to assess changes in anxiety, depression, and functional outcomes. Analyses followed an Intent-to-Treat protocol, with Minimal Clinically Important Difference (MCID) used to identify meaningful improvements through post-hoc analyses. Results: ButyraGen significantly reduced self-reported anxiety in men, who were over twice as likely to achieve clinically meaningful improvement versus placebo. Across all participants, improvements in feelings of fear and unease were observed. No overall benefit for self-reported depression was seen, but participants without gastrointestinal disease had a twofold greater likelihood of improvement compared to placebo. Further analysis showed improvements in hopelessness and helplessness among younger adults and men. Functional improvements were also seen for reduced distraction and improved social engagement. Conclusion: These results suggest that ButyraGen may supports both psychological and physiological well-being, particularly in men, younger individuals, and those without gastrointestinal disease. Benefits began to appear within weeks two and three and were sustained through six weeks, highlighting its potential as a fast-acting intervention for both gut and brain health, indicative of the gut-brain axis connection. Keywords: ButyraGen, cognitive, digestion, butyrate, mood, psychological well-being

Nutrition and Dietary SupplementsVol. Volume 17
Miles College (US), University of New England (US)
Openalex Percentile: Top 63%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.